Results 141 to 150 of about 104,177 (305)
ABSTRACT Background Bimekizumab, a monoclonal antibody targeting interleukin (IL)‐17A and IL‐17F, has shown efficacy in psoriatic arthritis (PsA) clinical trials, but real‐world data on its effectiveness are limited. This study aimed to evaluate its real‐world effectiveness in PsA patients treated in dermatologic settings.
Giacomo Caldarola +12 more
wiley +1 more source
5-Fluorocytosine and Urinary Candidiasis [PDF]
R.R. Davies, D. S. Reeves
openalex +1 more source
ABSTRACT Background and Aim Though liver transplantation (LT) is effective for pediatric patients with end‐stage liver disease, it is associated with complications such as graft‐versus‐host disease (GVHD). In part due to its rarity and lack of standardized therapy, post‐LT GVHD is associated with a high mortality rate.
Keisuke Sawada +5 more
wiley +1 more source
Amphotericin B in the treatment of candida meningitis in three neonates
Candidiasis is an opportunistic infection and may result in significant morbidity and mortality in neonates. Cerebral candidiasis is rare and usually associated with systemic candidiasis.
M Aydin +4 more
doaj
ROENTGENOGRAPHIC FEATURES OF PRIMARY RENAL CANDIDIASIS [PDF]
Richard D. Gerle
openalex +1 more source
Repositioning Antimicrobial Peptides Against WHO‐Priority Fungi
The growing burden of drug‐resistant fungal infections, driven by pathogens such as Candida auris, Cryptococcus neoformans, and Aspergillus fumigatus, underscores the urgent need for novel antifungal therapies. This review explores antimicrobial peptides as promising agents with membrane‐disruptive activity, immunomodulatory properties, and delivery ...
Cesar Augusto Roque‐Borda +12 more
wiley +1 more source
Physiological and metabolic alterations accompanying systemic candidiasis in mice [PDF]
R D Leunk, Robert J. Moon
openalex +1 more source
Changes in the epidemiological landscape of invasive candidiasis
F. Lamoth +3 more
semanticscholar +1 more source
A Rare Case of Blastomycosis in a Psoriasis Patient Treated With Ustekinumab (Stelara)
ABSTRACT Psoriasis is a chronic inflammatory skin condition mediated by T‐helper 1 (Th1) and T‐helper 17 (Th17) cytokines, including interleukin (IL)‐12, IL‐23, IL‐17, and tumor necrosis factor alpha (TNF‐α). Ustekinumab, a human monoclonal antibody against the p40 subunit of IL‐12/23, has revolutionized treatment of moderate to severe psoriasis but ...
Fatima Ghaffar +6 more
wiley +1 more source
Studies on the Experimental Chemotherapy for Dermatomycosis and Candidiasis. I
Hiroshi Yamazoe
openalex +2 more sources

